KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Vir Biotechnology (VIR) Equity Income (2021 - 2025)

Vir Biotechnology's Equity Income history spans 5 years, with the latest figure at -$2.6 million for Q4 2025.

  • On a quarterly basis, Equity Income fell 133.73% to -$2.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.8 million, a 132.49% increase, with the full-year FY2025 number at $1.7 million, up 131.44% from a year prior.
  • Equity Income hit -$2.6 million in Q4 2025 for Vir Biotechnology, down from $1.3 million in the prior quarter.
  • Over the last five years, Equity Income for VIR hit a ceiling of $164.1 million in Q3 2021 and a floor of -$95.0 million in Q1 2022.
  • Historically, Equity Income has averaged $75166.7 across 5 years, with a median of -$2.6 million in 2023.
  • The widest YoY moves for Equity Income: up 208.2% in 2025, down 945.5% in 2025.
  • Tracing VIR's Equity Income over 5 years: stood at -$26.0 million in 2021, then soared by 134.27% to $8.9 million in 2022, then crashed by 111.26% to -$1.0 million in 2023, then dropped by 9.56% to -$1.1 million in 2024, then crashed by 133.73% to -$2.6 million in 2025.
  • Business Quant data shows Equity Income for VIR at -$2.6 million in Q4 2025, $1.3 million in Q3 2025, and -$3.4 million in Q2 2025.